Other
Gemcitabine
0
Pipeline Programs↗
6
Active Trials↗
16
Companies Involved↗
Gemcitabine is an early-stage landscape with 0 programs across 16 companies. The most active players are Eli Lilly, AstraZeneca, Boehringer Ingelheim.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
76
clinical trials
Completed44 · 58%
Terminated15 · 20%
Unknown status6 · 8%
Withdrawn5 · 7%
Active, not recruiting3 · 4%
Recruiting2 · 3%
Other1 · 1%
Clinical Trials
Trial Activity
76 trials
Pazopanib Vs. Pazopanib Plus Gemcitabine
Active, not recruiting·NNorth Eastern German Society of Gynaecological Oncology·Phase 2·NCT02203760·58 enrolled
Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT07189793·106 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)